The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients

Introduction: The use of FOLFOXIRI (oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil) as first-line therapy for metastatic colorectal cancer (mCRC) is well-established. However, there is no data about the effectiveness of this regimen in pretreated patients in the current literature. In this...

Full description

Bibliographic Details
Main Authors: Ibrahim Yildiz, Halil Taskaynatan, Umut Varol, Tarik Salman, Utku Oflazoglu, Yasar Yildiz, Yuksel Kucukzeybek, Ahmet Alacacioglu, Mustafa Oktay Tarhan
Format: Article
Language:English
Published: Turkiye Klinikleri 2018-04-01
Series:Journal of Oncological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S2452336417301310
id doaj-99ee47e43cb14facb54811693dde1939
record_format Article
spelling doaj-99ee47e43cb14facb54811693dde19392020-11-25T01:41:11ZengTurkiye KlinikleriJournal of Oncological Sciences2452-33642018-04-01416061The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patientsIbrahim Yildiz0Halil Taskaynatan1Umut Varol2Tarik Salman3Utku Oflazoglu4Yasar Yildiz5Yuksel Kucukzeybek6Ahmet Alacacioglu7Mustafa Oktay Tarhan8Acibadem University Atakent Hospital, Istanbul, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey; Corresponding author. Medical Oncology Clinic, Izmir Katıp Celebi University, Ataturk Training and Research Hospital, 35360 Izmir, Turkey.Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyInstitute of Oncology, Dokuz Eylul University, Izmir, TurkeyIntroduction: The use of FOLFOXIRI (oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil) as first-line therapy for metastatic colorectal cancer (mCRC) is well-established. However, there is no data about the effectiveness of this regimen in pretreated patients in the current literature. In this case report, we aim to evaluate the efficacy and benefit of FOLFOXIRI in patients who received standard regimens. Case report: 3 patients were treated with FOLFOXIRI and 1 patient received FOLFOXIRI + bevasizumab. Three patients had a partial response to FOLFOXIRI; one of these patients showed disease progression on this chemotherapy regimen and died. Progression free survival (PFS) of three patients was 5.5, 9 and 7.5 months respectively. One patient showed progression without any response to treatment. Conclusion: We observed a partial response in 3 patients who were treated with FOLFOXİRİ and their progression-free survival was more than 3 months. These patients were treated with FOLFOXİRİ as a third or fourth line therapy. FOLFOXIRI should be considered as an alternative option in patients who have received standard treatments with good performance status. Keywords: Colorectal cancer, FOLFOXIRI, Metastatic, Chemorefractoryhttp://www.sciencedirect.com/science/article/pii/S2452336417301310
collection DOAJ
language English
format Article
sources DOAJ
author Ibrahim Yildiz
Halil Taskaynatan
Umut Varol
Tarik Salman
Utku Oflazoglu
Yasar Yildiz
Yuksel Kucukzeybek
Ahmet Alacacioglu
Mustafa Oktay Tarhan
spellingShingle Ibrahim Yildiz
Halil Taskaynatan
Umut Varol
Tarik Salman
Utku Oflazoglu
Yasar Yildiz
Yuksel Kucukzeybek
Ahmet Alacacioglu
Mustafa Oktay Tarhan
The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients
Journal of Oncological Sciences
author_facet Ibrahim Yildiz
Halil Taskaynatan
Umut Varol
Tarik Salman
Utku Oflazoglu
Yasar Yildiz
Yuksel Kucukzeybek
Ahmet Alacacioglu
Mustafa Oktay Tarhan
author_sort Ibrahim Yildiz
title The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients
title_short The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients
title_full The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients
title_fullStr The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients
title_full_unstemmed The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients
title_sort role of folfoxiri in chemorefractory metastatic colorectal cancer patients
publisher Turkiye Klinikleri
series Journal of Oncological Sciences
issn 2452-3364
publishDate 2018-04-01
description Introduction: The use of FOLFOXIRI (oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil) as first-line therapy for metastatic colorectal cancer (mCRC) is well-established. However, there is no data about the effectiveness of this regimen in pretreated patients in the current literature. In this case report, we aim to evaluate the efficacy and benefit of FOLFOXIRI in patients who received standard regimens. Case report: 3 patients were treated with FOLFOXIRI and 1 patient received FOLFOXIRI + bevasizumab. Three patients had a partial response to FOLFOXIRI; one of these patients showed disease progression on this chemotherapy regimen and died. Progression free survival (PFS) of three patients was 5.5, 9 and 7.5 months respectively. One patient showed progression without any response to treatment. Conclusion: We observed a partial response in 3 patients who were treated with FOLFOXİRİ and their progression-free survival was more than 3 months. These patients were treated with FOLFOXİRİ as a third or fourth line therapy. FOLFOXIRI should be considered as an alternative option in patients who have received standard treatments with good performance status. Keywords: Colorectal cancer, FOLFOXIRI, Metastatic, Chemorefractory
url http://www.sciencedirect.com/science/article/pii/S2452336417301310
work_keys_str_mv AT ibrahimyildiz theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT haliltaskaynatan theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT umutvarol theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT tariksalman theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT utkuoflazoglu theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT yasaryildiz theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT yukselkucukzeybek theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT ahmetalacacioglu theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT mustafaoktaytarhan theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT ibrahimyildiz roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT haliltaskaynatan roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT umutvarol roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT tariksalman roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT utkuoflazoglu roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT yasaryildiz roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT yukselkucukzeybek roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT ahmetalacacioglu roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
AT mustafaoktaytarhan roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients
_version_ 1725042121821388800